FCF Margin % is calculated as Free Cash Flow divided by its Revenue. BioCardia's Free Cash Flow for the
three
months ended in Sep. 2024 was $-2.61 Mil. BioCardia's Revenue for the
three
months ended in Sep. 2024 was $0.00 Mil. Therefore, BioCardia's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.
The historical rank and industry rank for BioCardia's FCF Margin % or its related term are showing as below:
BCDA'
s FCF Margin % Range Over the Past 10 Years
Min: -10287.32 Med: -1191.78 Max: 64.02
Current: -10287.32
During the past 13 years, the highest FCF Margin % of BioCardia was 64.02%. The lowest was -10287.32%. And the median was -1191.78%.
BCDA's FCF Margin % is ranked worse than 92.43% of 1017
companies
in the Biotechnology industry
Industry Median: -142.95
vs BCDA: -10287.32
BioCardia FCF Margin % Historical Data
The historical data trend for BioCardia's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of BioCardia's FCF Margin %
For the Biotechnology subindustry, BioCardia's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioCardia's FCF Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioCardia's FCF Margin % distribution charts can be found below:
* The bar in red indicates where BioCardia's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioCardia FCF Margin % Related Terms
Thank you for viewing the detailed overview of BioCardia's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BCDA has been successfully added to your 